Skip to main content

Table 1 Baseline characteristics of the Mannheim Sepsis Study (MaSep)

From: Diagnostic and prognostic utility of soluble CD 14 subtype (presepsin) for severe sepsis and septic shock during the first week of intensive care treatment

  Controls SIRS Sepsis Severe sepsis Septic shock
(n = 60) (n = 9) (n = 5) (n = 28) (n = 74)
Age, years (mean, range) 62 (42 to 87) 74 (61 to 81) 66 (50 to 81) 66 (26 to 87) 68 (26 to 88)
Gender, n (%)      
Male 29 (48) 5 (56) 4 (80) 21 (75) 52 (70)
Female 31 (52) 4 (44) 1 (20) 7 (25) 22 (30)
Site of infection, n (%)
Lung - - 5 (100) 20 (71) 41 (55)
Urinary tract - - - 3 (11) 4 (5)
Abdominal - - - 3 (11) 12 (16)
Central nervous system - - - - -
Skin - - - 1 (4) 3 (4)
Heart - - - - -
Neutropenia - - - - -
Blood - - - 1 (4) 7 (10)
Others - - - - 7 (10)
Laboratory values, mean ± SEM
White blood cells, 109/L - 14.5 ± 1.7 19.2 ± 3.1 17.4 ± 3.1 19.5 ± 1.8
Platelets, 109/L - 210 ± 216 305 ± 202 218 ± 214 191 ± 142
Bilirubin, mg/dl - 0.8 ± 0.2 0.5 ± 0.1 1.1 ± 0.3 2.9 ± 0.7
Creatinine, mg/dl - 1.1 ± 0.1 1.2 ± 0.2 2.4 ± 0.3 2.7 ± 0.2
C-reactive protein, mg/L - 68 ± 16 155 ± 28 178 ± 24 197 ± 12
Procalcitonin, ng/ml - 2.0 ± 0.9 4.3 ± 2.8 6.9 ± 2.0 22.2 ± 4
Interleukin 6, pg/ml - 335 ± 154 142 ± 53 1,385 ± 829 21,089 ± 15,437
pCO2, mmHg - 43 ± 5 49 ± 14 45 ± 4 44 ± 2
Positive blood cultures, n (%) - 0 (0) 0 (0) 8 (29) 25 (34)
ICU parameters, mean ± SEM
ICU days - 10 ± 2 8 ± 2 10 ± 2 15 ± 2
Ventilation days - 3 ± 1 4 ± 2 6 ± 2 9 ± 2
Catecholamine days - 2 ± 1 0 ± 0 2 ± 1 7 ± 1
Renal replacement therapy days - 0 ± 0 0 ± 0 1 ± 0.6 3 ± 1
APACHE II, mean ± SEM - 24 ± 2 18 ± 3 20 ± 2 27 ± 1
SOFA score, mean ± SEM - 7.6 ± 1.1 6.2 ± 1.8 6.1 ± 0.5 11.8 ± 0.4
All-cause mortality, n (%)      
30 days      
Death 0 (0) 4 (44) 2 (40) 10 (36) 42 (57)
Survivor 60 (100) 5 (56) 3 (60) 18 (64) 32 (43)
6 months      
Death 0 (0) 4 (44) 3 (60) 12 (43) 53 (72)
Survivor 60 (100) 5 (56) 2 (40) 16 (57) 21 (28)
  1. SIRS, systemic inflammatory response syndrome; SEM, standard error of the mean; APACHE II, acute physiology and chronic health evaluation II; SOFA, sequential organ failure assessment.